Samedi, 24 Octobre 2020
Dernières nouvelles
Principale » Rigel Pharmaceuticals, Inc. (RIGL) Releases Earnings Results, Beats Estimates By $0.01 EPS

Rigel Pharmaceuticals, Inc. (RIGL) Releases Earnings Results, Beats Estimates By $0.01 EPS

26 Novembre 2017

The total amount of shares outstanding is 149.19 million, giving the company a market capitalization of about 634.06 million.

A number of research firms have weighed in on RIGL. Jefferies Group analyst E. Yang forecasts that the biotechnology company will earn ($0.13) per share for the quarter. The firm now has $3.25 price target on the biotechnology company's stock. HC Wainwright restated a "buy" rating and set a $7.00 price target on shares of Rigel Pharmaceuticals in a research report on Monday, November 6th. 621,636 shares of the company traded hands, compared to its average volume of 1,210,332.

Previously Rigel Pharmaceutical (NASDAQ:RIGL) reported $-0.14 earnings per share (EPS) for the quarter, beating the consensus estimate of $-0.15 by $0.01. Rigel Pharmaceuticals has a consensus rating of "Hold" and a consensus target price of $5.31.

Zacks Investment Research upgraded shares of Rigel Pharmaceuticals, Inc.

Niantic rounds up $200 million ahead of Harry Potter game
Earlier this year, Niantic made its first acquisition of mobile social network developer, Evertoon. Pokemon Go maker Niantic has caught itself $200 million in funding.

Rigel Pharmaceutical (NASDAQ:RIGL) shares traded 7.87% up during most recent session to reach at the closing price of $4.25. The Return on Equity (ROE) value stands at -102.3%. The business's revenue was down 76.1% on a year-over-year basis. "(NASDAQ:RIGL) Expected to Post FY2017 Earnings of ($0.56) Per Share" was originally reported by TrueBlueTribune and is owned by of TrueBlueTribune. Wells Fargo & Company MN boosted its holdings in Rigel Pharmaceuticals by 116.9% in the 3rd quarter. Marshall Wace North America L.P. bought a new stake in shares of Rigel Pharmaceuticals during the first quarter worth approximately $5,935,000. Macquarie Group Ltd. now owns 734,088 shares of the biotechnology company's stock valued at $1,865,000 after purchasing an additional 99,088 shares during the last quarter. Finally, Candriam Luxembourg S.C.A. grew its position in shares of Rigel Pharmaceuticals by 8.8% during the second quarter. Candriam Luxembourg S.C.A. now owns 1,265,000 shares of the biotechnology company's stock valued at $3,213,000 after purchasing an additional 85,000 shares during the last quarter. FMR LLC raised its position in shares of Rigel Pharmaceuticals by 23.6% in the first quarter. Institutional investors refer to nonbank organizations that purchase bulk quantities of public companies, and they are qualified for lower fees and other perks compared to average stock buyers - organizations like hedge funds, for example. Wellington Management Group LLP now owns 13,843,629 shares of the biotechnology company's stock worth $45,823,000 after buying an additional 3,282,390 shares during the period. Following the transaction, the chief financial officer now owns 100,000 shares of the company's stock, valued at $390,000.

According to analysts Rigel Pharmaceutical (NASDAQ:RIGL)'s minimum EPS for the current quarter is at $-0.13 and can go high up to $-0.13.

According to Rigel Pharmaceuticals, Inc.'s latest 13F filing with the US Securities and Exchange Commission (SEC), institutional ownership is at 74.53%. Vanguard Group Inc. now owns 5,691,035 shares of the biotechnology company's stock worth $18,837,000 after buying an additional 960,345 shares during the period. If you are viewing this piece of content on another domain, it was illegally stolen and republished in violation of USA & worldwide copyright legislation.

Rigel Pharmaceuticals, Inc. has had 1 insider trades in the last 3 months, including 0 open market buys and 1 sells. The Company is engaged in the discovering, developing and providing novel small molecule drugs that improve the lives of patients with immune and hematological disorders, cancer and rare diseases. The Company's pioneering research focuses on intracellular signaling pathways and related targets that are critical to disease mechanisms.